Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides.
Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides.
复制标题
使用内源性蛋白质和肽的分子磁共振成像区分神经胶质瘤和放射性坏死
作者：
脑肿瘤治疗后肿瘤复发与放射性坏死的鉴别仍然很困难。在这里，我们表明这些病变可以使用内源性细胞蛋白质和肽的酰胺质子转移（APT）磁共振成像（MRI）信号作为成像生物标志物来区分。将两种原位胶质瘤（SF188/V+胶质瘤和9L胶质瘤）模型与大鼠放射坏死模型进行比较，我们可以通过APT MRI清楚地区分活的胶质瘤（高强度）和放射坏死（低强度到等强度）。当我们对U87MG胶质瘤大鼠进行照射时，照射后3 d和6 d，肿瘤内的APT信号明显下降。APT可以检测到的酰胺质子提供了一种独特的、无创的MRI生物标志物，用于区分可存活的恶性肿瘤和放射性坏死，并预测肿瘤对治疗的反应。
It remains difficult to distinguish tumor recurrence from radiation necrosis after brain tumor therapy. Here we show that these lesions can be distinguished using the amide proton transfer (APT) magnetic resonance imaging (MRI) signals of endogenous cellular proteins and peptides as an imaging biomarker. When comparing two models of orthotopic glioma (SF188/V+ glioma and 9L gliosarcoma) with a model of radiation necrosis in rats, we could clearly differentiate viable glioma (hyperintense) from radiation necrosis (hypointense to isointense) by APT MRI. When we irradiated rats with U87MG gliomas, the APT signals in the irradiated tumors had decreased substantially by 3 d and 6 d after radiation. The amide protons that can be detected by APT provide a unique and noninvasive MRI biomarker for distinguishing viable malignancy from radiation necrosis and predicting tumor response to therapy.